Scarica l'app Stockscreener
7.57
2.44%
0.18
Dopo l'orario di chiusura:
7.63
0.06
+0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
107,820 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Acquired by Wellington Management Group LLP - MarketBeat
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
XTX Topco Ltd Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
State Street Corp Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap DownHere's Why - MarketBeat
Biocryst Pharmaceuticals director Nancy Hutson sells $52,780 in stock - Investing.com
Verition Fund Management LLC Sells 102,839 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy - Seeking Alpha
Charles Schwab Investment Management Inc. Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Two Sigma Advisers LP Acquires 261,500 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
The Manufacturers Life Insurance Company Has $2.27 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Jacobs Levy Equity Management Inc. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Yahoo Finance
BNP Paribas Financial Markets Has $3.78 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals Awards Stock Options, RSUs to New Employees in Inducement Package - StockTitan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.60 Consensus Target Price from Analysts - MarketBeat
Cinctive Capital Management LP Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is Caligan Partners LP's 7th Largest Position - MarketBeat
Fisher Asset Management LLC Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
(BCRX) On The My Stocks Page - Stock Traders Daily
Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Simply Wall St
Algert Global LLC Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $5.19 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Principal Financial Group Inc. Purchases 375,890 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Orladeyo now available to treat HAE patients in Ireland - Angioedema News Today
Hereditary Angioedema Therapeutics Market Report Outlines - openPR
Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR
Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat
BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland - StockTitan
BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire
(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Avian influenza Treatment Market Growth Trends: Regional - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat
BioCryst's SWOT analysis: stock outlook amid orladeyo success, pipeline shifts - Investing.com UK
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com
HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat
Clearside's Eye Treatment Platform Gains Momentum with Major Santen Partnership in China - StockTitan
Ionis Looks Ahead To Commercializing Its Own Products - Citeline
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com
BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):